InsiderTrades.com logo

TSBX Insider Trading

Insider Ownership Percentage: 32.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Turnstone Biologics Insider Trading History Chart

This chart shows the insider buying and selling history at Turnstone Biologics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Turnstone Biologics Share Price & Price History

Current Price: $0.37
Price Change: ▲ Price Increase of +0.0007 (0.19%)
As of 03/14/2025 05:00 PM ET

This chart shows the closing price history over time for TSBX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Turnstone Biologics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/25/2023Versant Ventures V, LlcMajor ShareholderBuy225,000$12.00$2,700,000.002,726,322View SEC Filing Icon  
7/20/2023Rishi GuptaDirectorBuy416,666$12.00$4,999,992.003,099,265View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Turnstone Biologics (NASDAQ:TSBX)

52.51% of Turnstone Biologics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TSBX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Turnstone Biologics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/17/2025Millennium Management LLC73,744$37K0.0%-28.4%0.319%Search for SEC Filing on Google Icon
2/12/2025Takeda Pharmaceutical Co. Ltd.895,824$0.45M1.7%N/A3.873%Search for SEC Filing on Google Icon
11/15/2024Point72 Asset Management L.P.932,226$0.52M0.0%-16.7%4.030%Search for SEC Filing on Google Icon
11/13/2024FMR LLC1,172,987$0.65M0.0%+3.3%5.071%Search for SEC Filing on Google Icon
8/19/2024Point72 Asset Management L.P.1,118,588$2.93M0.0%-5.5%4.837%Search for SEC Filing on Google Icon
8/13/2024Sei Investments Co.11,882$31K0.0%N/A0.051%Search for SEC Filing on Google Icon
5/17/2024Zimmer Partners LP179,026$0.47M0.0%+271.4%0.774%Search for SEC Filing on Google Icon
4/17/2024Kathleen S. Wright Associates Inc.42,553$0.11M0.1%N/A0.184%Search for SEC Filing on Google Icon
2/15/2024PFM Health Sciences LP633,313$1.61M0.1%-58.5%2.742%Search for SEC Filing on Google Icon
2/15/2024Caas Capital Management LP45,831$0.12M0.0%-40.1%0.198%Search for SEC Filing on Google Icon
12/6/2023Citigroup Inc.7,524$30K0.0%N/A0.033%Search for SEC Filing on Google Icon
11/15/2023Sectoral Asset Management Inc.517,648$2.04M0.4%N/A2.266%Search for SEC Filing on Google Icon
11/14/2023Eventide Asset Management LLC708,317$2.79M0.1%N/A3.101%Search for SEC Filing on Google Icon
11/13/2023FMR LLC2,830,284$11.15M0.0%N/A12.392%Search for SEC Filing on Google Icon
11/7/2023New York State Common Retirement Fund18,867$74K0.0%N/A0.083%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Turnstone Biologics logo
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
Read More on Turnstone Biologics

Today's Range

Now: $0.37
Low: $0.35
High: $0.39

50 Day Range

MA: $0.43
Low: $0.35
High: $0.58

52 Week Range

Now: $0.37
Low: $0.34
High: $3.88

Volume

43,853 shs

Average Volume

226,411 shs

Market Capitalization

$8.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.04

Who are the company insiders with the largest holdings of Turnstone Biologics?

Turnstone Biologics' top insider investors include:
  1. Rishi Gupta (Director)
  2. Versant Ventures V, Llc (Major Shareholder)
Learn More about top insider investors at Turnstone Biologics.

Who are the major institutional investors of Turnstone Biologics?

Turnstone Biologics' top institutional investors include:
  1. Takeda Pharmaceutical Co. Ltd. — 3.87%
  2. Millennium Management LLC — 0.32%
Learn More about top institutional investors of Turnstone Biologics stock.

Which major investors are selling Turnstone Biologics stock?

Within the last quarter, TSBX stock was sold by these institutional investors:
  1. Millennium Management LLC

Which major investors are buying Turnstone Biologics stock?

In the previous quarter, TSBX stock was purchased by institutional investors including:
  1. Takeda Pharmaceutical Co. Ltd.
Within the previous year, these company insiders have bought Turnstone Biologics stock:
  1. Rishi Gupta (Director)
  2. Versant Ventures V, Llc (Major Shareholder)
Learn More investors buying Turnstone Biologics stock.